基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议

2017-03-20 中国心血管相关专家小组(统称) 中华全科医师杂志.2017,16(3):169-173.

心力衰竭(心衰)是由于各种心脏结构和/或功能异常导致心室充盈和/或射血能力受损的一组复杂的临床综合征。心衰发病率高,诊断和治疗困难,在全面临床评估和分析的基础上,合理地将生物标志物应用于其诊疗可起到事半功倍的效果。目前生物标志物可用于心衰的诊断、临床评估和预后评价等方面,其中,利钠肽家族中的B型利钠肽(BNP)和N末端B型利钠肽原(NT—proBNP)应用尤其广泛,本建议旨在为基层医院医师在心衰诊

中文标题:

基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议

发布日期:

2017-03-20

简要介绍:

心力衰竭(心衰)是由于各种心脏结构和/或功能异常导致心室充盈和/或射血能力受损的一组复杂的临床综合征。心衰发病率高,诊断和治疗困难,在全面临床评估和分析的基础上,合理地将生物标志物应用于其诊疗可起到事半功倍的效果。目前生物标志物可用于心衰的诊断、临床评估和预后评价等方面,其中,利钠肽家族中的B型利钠肽(BNP)和N末端B型利钠肽原(NT—proBNP)应用尤其广泛,本建议旨在为基层医院医师在心衰诊疗中合理应用这两项指标提供一些依据。

 

拓展指南:心力衰竭相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议)] GetToolGuiderByIdResponse(projectId=1, id=2e3641c001ae3221, title=基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议, enTitle=, guiderFrom=中华全科医师杂志.2017,16(3):169-173., authorId=null, author=, summary=心力衰竭(心衰)是由于各种心脏结构和/或功能异常导致心室充盈和/或射血能力受损的一组复杂的临床综合征。心衰发病率高,诊断和治疗困难,在全面临床评估和分析的基础上,合理地将生物标志物应用于其诊疗可起到事半功倍的效果。目前生物标志物可用于心衰的诊断、临床评估和预后评价等方面,其中,利钠肽家族中的B型利钠肽(BNP)和N末端B型利钠肽原(NT—proBNP)应用尤其广泛,本建议旨在为基层医院医师在心衰诊, cover=, journalId=null, articlesId=null, associationId=306, associationName=中国心血管相关专家小组(统称), associationIntro=本制定者非特指某个专家小组,为统称。, copyright=0, guiderPublishedTime=Mon Mar 20 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>心力衰竭(心衰)是由于各种心脏结构和/或功能异常导致心室充盈和/或射血能力受损的一组复杂的临床综合征。心衰发病率高,诊断和治疗困难,在全面临床评估和分析的基础上,合理地将生物标志物应用于其诊疗可起到事半功倍的效果。目前生物标志物可用于心衰的诊断、临床评估和预后评价等方面,其中,利钠肽家族中的B型利钠肽(BNP)和N末端B型利钠肽原(NT—proBNP)应用尤其广泛,本建议旨在为基层医院医师在心衰诊疗中合理应用这两项指标提供一些依据。 </P> <P> </P>拓展指南:<strong>与<font color=red>心力衰竭</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=9a0cf1c001a684db" title="从指南到临床—再读2017ACC/AHA/HFSA心力衰竭处理指南" target=_blank>从指南到临床—再读2017ACC/AHA/HFSA心力衰竭处理指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ddf9f1c001a243fa" title="ESC2016指南建议:伊伐布雷定在心力衰竭治疗中的作用" target=_blank>ESC2016指南建议:伊伐布雷定在心力衰竭治疗中的作用</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4b3ba1c001a24102" title="2017 ACC/AHA/HFSA指南:心力衰竭的管理(更新版)" target=_blank>2017 ACC/AHA/HFSA指南:心力衰竭的管理(更新版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d83fb1c001a065da" title="【精品指南】 2016 ESC:欧洲急慢性心力衰竭诊治指南要点总结" target=_blank>【精品指南】 2016 ESC:欧洲急慢性心力衰竭诊治指南要点总结</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1e8071c001a051a8" title="2016 AHA科学声明:先天性心脏病患者的慢性心力衰竭" target=_blank>2016 AHA科学声明:先天性心脏病患者的慢性心力衰竭</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E5%8A%9B%E8%A1%B0%E7%AB%AD" target=_blank>有关心力衰竭更多指南</a></ul>, tagList=[TagDto(tagId=335, tagName=心力衰竭), TagDto(tagId=11762, tagName=利钠肽)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5898, appHits=469, showAppHits=8, pcHits=3850, showPcHits=2450, likes=122, shares=18, comments=3, approvalStatus=1, publishedTime=Mon Jul 24 22:30:47 CST 2017, publishedTimeString=2017-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jul 24 22:30:47 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:11:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议)])
基层医院心力衰竭临床诊疗中B型利钠肽和N末端B型利钠肽原的应用中国专家建议
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2090626, encodeId=86f3209062683, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ggUia6x7V63JcoTzVD8PmWoibD02J8jNFq4zrbMes9IDSJncndbsmpONoRNWNyco0nKNJBibkKA550ses1r6X26w/132, createdBy=2af65329552, createdName=ff1533, createdTime=Tue Sep 27 13:54:40 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239373, encodeId=cc0d12393e344, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a09e2550843, createdName=1254052em82(暂无昵称), createdTime=Wed Aug 17 20:43:12 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231596, encodeId=475b2315967e, content=学习了!~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20221980208, createdName=绿茶小仙, createdTime=Tue Aug 08 20:45:06 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2022-09-27 ff1533

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2090626, encodeId=86f3209062683, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ggUia6x7V63JcoTzVD8PmWoibD02J8jNFq4zrbMes9IDSJncndbsmpONoRNWNyco0nKNJBibkKA550ses1r6X26w/132, createdBy=2af65329552, createdName=ff1533, createdTime=Tue Sep 27 13:54:40 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239373, encodeId=cc0d12393e344, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a09e2550843, createdName=1254052em82(暂无昵称), createdTime=Wed Aug 17 20:43:12 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231596, encodeId=475b2315967e, content=学习了!~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20221980208, createdName=绿茶小仙, createdTime=Tue Aug 08 20:45:06 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2090626, encodeId=86f3209062683, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ggUia6x7V63JcoTzVD8PmWoibD02J8jNFq4zrbMes9IDSJncndbsmpONoRNWNyco0nKNJBibkKA550ses1r6X26w/132, createdBy=2af65329552, createdName=ff1533, createdTime=Tue Sep 27 13:54:40 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239373, encodeId=cc0d12393e344, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a09e2550843, createdName=1254052em82(暂无昵称), createdTime=Wed Aug 17 20:43:12 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231596, encodeId=475b2315967e, content=学习了!~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20221980208, createdName=绿茶小仙, createdTime=Tue Aug 08 20:45:06 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 绿茶小仙

    学习了!~

    0